Successful Combination of Sunitinib and Girentuximab in Two Renal Cell Carcinoma Animal Models: A Rationale for Combination Treatment of Patients with Advanced RCC

Successful Combination of Sunitinib and Girentuximab in Two Renal Cell Carcinoma Animal Models: A Rationale for Combination Treatment of Patients with Advanced RCC

Anti-angiogenic treatment with tyrosine kinase inhibitors (TKI) has lead to an impressive increase in progression-free survival for patients with metastatic RCC (mRCC), but mRCC remains largely incurable. We combined sunitinib, targeting the endothelial cells with Girentuximab (monoclonal antibody c...

Full description

Bibliographic Details
Main Authors: Oosterwijk-Wakka, Jeannette C., de Weijert, Mirjam C.A., Franssen, Gerben M., Leenders, William P.J., van der Laak, Jeroen A.W.M., Boerman, Otto C., Mulders, Peter F.A., Oosterwijk, Egbert
Format: Online
Language:English
Published: Neoplasia Press 2015
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4351300/

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4351300/

Similar Items